All In Biotech

Drug Trial Radar · NCT05730036

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

Sep 18, 2023

Primary completion

Apr 19, 2033

Study completion Apr 19, 2033

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Feb 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had advanced multiple myeloma that returned and needed to be treated again after many other therapies had failed. These participants were no longer benefiting from standard medications and had no good treatment options. In that study, some participants who were treated with linvoseltamab had improvement of their myeloma (shrinkage of their tumors), including some participants who had complete responses (that is, the treatment got rid of all evidence of myeloma in their bodies). This study is focused on participants who have multiple myeloma that has returned or needs to be treated again after one to four prior treatments and have standard cancer treatment options available to them. The aim of this study is to see how safe and effective linvoseltamab is compared to a combination of three cancer drugs: elotuzumab, pomalidomide and dexamethasone, (called EPd) in participants who have returned after having received prior treatment that included lenalidomide, a proteosome inhibitor, and (for participants in some countries) a cluster of differentiation 38 (CD38) antibody. Half of the participants in this study will get linvoseltamab, and the other half will get EPd. This study is looking at several other research questions, including: * How long participants benefit from receiving linvoseltamab compared with EPd * How many participants treated with linvoseltamab or EPd have improvement of their multiple myeloma and by how much * What side effects happen from taking linvoseltamab compared to EPd * How long participants live while receiving treatment or after treatment with linvoseltamab compared to EPd * If there is any improvement in pain after treatment with linvoseltamab compared to EPd

Conditions

  • Relapsed Refractory Multiple Myeloma (RRMM)

Interventions

  • LinvoseltamabDrug

    REGN5458 will be administered by intravenous (IV) infusion

  • ElotuzumabDrug

    Elotuzumab will be administered by IV infusion

  • PomalidomideDrug

    Pomalidomide capsules will be administered by mouth (PO)

  • DexamethasoneDrug

    Dexamethasone tablets/capsules will be administered PO and/or by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participantsTime frame: Up to approximatively 5 years

Locations

159 sites in 18 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA)

    Los Angeles, California · Active not recruiting

  • University of Florida Division of Sponsored Programs

    Gainesville, Florida · Withdrawn

  • University of Kentucky, Markey Cancer Center Clinical Research Organization

    Lexington, Kentucky · Active not recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Active not recruiting

  • Stony Brook University

    Stony Brook, New York · Active not recruiting

  • Levine Cancer Center

    Charlotte, North Carolina · Active not recruiting

  • Duke University Medical Center

    Durham, North Carolina · Withdrawn

  • Kaiser Permanente Northwest

    Portland, Oregon · Active not recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • University of Washington

    Seattle, Washington · Active not recruiting

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia · Active not recruiting

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Active not recruiting

  • Icon Cancer Centre - Wesley

    Auchenflower, Queensland, Australia · Active not recruiting

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia · Active not recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Active not recruiting

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia · Active not recruiting

  • Launceston General Hospital

    Launceston, Tasmania, Australia · Active not recruiting

  • St Vincent's Hospital

    Fitzroy, Victoria, Australia · Active not recruiting

  • University Hospital Geelong

    Geelong, Victoria, Australia · Active not recruiting

  • Austin Hospital

    Heidelberg, Victoria, Australia · Active not recruiting

  • One Clinical Research at Hollywood Private Hospital

    Nedlands, Western Australia, Australia · Active not recruiting

  • Ziekenhuis Netwerk Antwerpen Stuivenberg

    Antwerp, Belgium · Active not recruiting

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Withdrawn

  • Clinique Universitaire de Mont Godinne

    Yvoir, Namur, Belgium · Completed

  • AZ Delta Algemeen Ziekenhuis Delta

    Roeselare, West-Vlaanderen, Belgium · Active not recruiting

  • Instituto Americas de Ensino e Pesquisa

    Rio de Janeiro, Brazil · Active not recruiting

  • A Beneficencia Portuguesa de Sao Paulo, Oncology House

    São Paulo, Brazil · Active not recruiting

  • Instituto DOr de Pesquisa e Ensino

    São Paulo, Brazil · Active not recruiting

  • AC Camargo Cancer Center

    São Paulo, Brazil · Active not recruiting

  • Clinica Medica Sao Germano

    São Paulo, Brazil · Active not recruiting

  • IDOR - Sao Rafael Salvador Bahia

    Salvador, Estado de Bahia, Brazil · Active not recruiting

  • Hospital Erasto Gaertner

    Curitiba, Paraná, Brazil · Active not recruiting

  • Associacao Dr Bartholomeu Tacchini

    Bento Gonçalves, Rio Grande do Sul, Brazil · Active not recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting

  • Centro Gaucho Integrado

    Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting

  • Animi Unidade de Tratamento Oncologico

    Lages, Santa Catarina, Brazil · Active not recruiting

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada · Active not recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Active not recruiting

  • University Health Network-Princess Margaret Cancer Center

    Toronto, Ontario, Canada · Active not recruiting

  • Hospital Clinico Universidad de Los Andes

    Santiago, Las Condes, Chile · Active not recruiting

Showing 40 of 159 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.